Abbvie Inc
NYSE: ABBV
$164.99
-$4.64 (-2.7%)
Closing Price on November 15, 2024
ABBV Articles
Despite the fact that energy has tumbled 20% from the highs posted in June, Jefferies remains bullish on the natural gas arena, and with good reason.
Published:
Last Updated:
Bristol-Myers Squibb released a better-than-expected second-quarter earnings report before the markets opened on Thursday.
Published:
Last Updated:
The short interest data have been released for the July 15 settlement date. For the selected pharmaceutical stocks, short interest was mixed.
Published:
Last Updated:
SunTrust Robinson Humphrey feels that the major pharmaceutical companies will outperform the rest of the year, and they cite new products, attractive dividends and solid performance as positives.
Published:
Last Updated:
In a study that ranks “perceived strength” of companies rather than their financial performance, Apple Inc. (NASDAQ: AAPL) took the top spot. Research firm Future Brand described it selection...
Published:
Last Updated:
24/7 Wall St. has put together a preview of Alphabet, Amazon.com, Facebook and some of the other major companies reporting their quarterly results this week.
Published:
Last Updated:
With yields plunging and the market getting very pricey, some top pharmaceutical stocks are starting to look like a great total return vehicle for the rest of this year and into 2017.
Published:
Last Updated:
The June 30 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short interest decreased.
Published:
Last Updated:
The broad markets are recovering in the wake of the Brexit and it really appears to be one big head fake. We are also realizing that the Brexit was a great opportunity to buy into the markets and...
Published:
Last Updated:
The short interest data have been released for the June 15 settlement date. Pharmaceutical companies usually are involved in a lengthy process in getting their drug candidates to market through...
Published:
Last Updated:
24/7 Wall St. has picked out the biggest movers and winners on Wednesday, particularly biopharma companies making serious runs in the session.
Published:
Last Updated:
Though Infinity Pharmaceuticals announced that its DYNAMO study met its primary endpoint of overall response rate, the stock was still way down on the day for other reasons.
Published:
Last Updated:
The Jefferies Healthcare Conference wrapped up in New York City last week, and the mood was reported as generally positive, with investors feeling much better than a few months ago.
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Friday morning include Abbvie, Amazon.com, Cliffs Natural Resources, Corning, Dynegy, Joy Global and Stanley Black & Decker.
Published:
Last Updated:
The May 31 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short interest was mixed.
Published:
Last Updated: